Press Room

AviaraDx presents at 2007 BIOCOM Investor Conference

Newly formed molecular diagnostic company launches two oncology tests

SAN DIEGO, Oct. 5/PRNewswire-FirstCall/ -- AviaraDx, Inc., announced today that the company is scheduled to provide a corporate overview of its molecular diagnostic test offerings and development programs at the 2007 BIOCOM Investor Conference.  The presentation is scheduled for Thursday, November 1st, at 2:30 p.m. in the Rancho Santa Fe ballroom of the San Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego, CA  92130.

About AviaraDx, Inc.
AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor.  Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will provide information critical to predict treatment response to a given therapeutic regimen.  AviaraDx offers diagnostic tests to qualified physicians or laboratories through its CAP-certified CLIA laboratory service operations.  The company's first diagnostic test offerings are based on its proprietary technologies for the molecular classification of metastatic cancer, CancerTYPE ID™, and its H/I™ (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:
Antonius Schuh, Ph.D.
Chief Executive Officer
+1 (760) 579  0500

| TOP |